factual
AveXis Pre-IPO Investment Outcome
RTW invested in AveXis at the pre-IPO round when it was about a $500 million company; it IPO'd in early 2016, a terrible year for biotech, and fell under pressure when venture investors sold six months later, but with only preclinical animal data RTW kept adding, and the company was sold to Novartis for almost $9 billion within about two years after an approved therapy.
factualpending
Speaker
StephanieEvidence Quote
“We got in at the pre-IPO round... they IPO-ed in early 2016, which was a terrible year for biotech... within two years, it was sold to Novartis for almost $9 billion”
Created: 11/13/2026, 1:54:32 PM
Your notes
Loading notes...